IVM is a better treatment than IVF for some people
A less painful, less costly option for treating infertility emerges
For people struggling to conceive, typical fertility treatment options like in vitro fertilization (IVF) can be taxing physically, emotionally and financially. However, advances in technology are helping to improve another less painful and costly option for treating infertility, known as in vitro maturation or IVM.
What is the difference between IVM and IVF?
In vitro maturation is surfacing as an alternative to in vitro fertilization that could "reduce the cost and time that fertility patients spend at the doctor's office and mitigate the side effects," said The Atlantic. IVF, the typical fertility treatment, "relies on hormone injections to ripen a crop of eggs inside the body," while IVM involves "collecting immature eggs from the ovaries and maturing them in the lab."
The first baby born from IVM was in Korea in 1991. Since then, "the method has generally yielded lower birth rates than IVF," said The Atlantic. It has historically generated fewer mature eggs and embryos than IVF, but those stats are improving with better technology. Although it maintains a lower success rate than IVF, IVM could still be "the better option for several groups of patients."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Compared with IVF, IVM is considerably less invasive and gentler on the patient. The former requires women to endure "multiple hormonal injections during the egg retrieval process to encourage egg maturation while the eggs are still in the ovaries," the American Pregnancy Association said. The latter procedure "matures the eggs after they have been retrieved, which makes the hormonal injections into the mother unnecessary." With fewer injections, fewer exams and labs needed, and a shorter time for the treatment, the cost for modern IVM procedures is "expected to be much lower than for IVF."
Who can benefit from IVM?
IVM offers several advantages compared to conventional IVF, including "reduced gonadotropin stimulation, minimal risk of ovarian hyperstimulation syndrome, reduced treatment times and lower costs," per the Journal of Reproductive Biology and Endocrinology. Decades after the first IVM birth, new scientific techniques are "raising the possibility that IVM could be a viable alternative to IVF — at least for some patients — and free thousands of aspiring mothers from brutal protocols," said The Atlantic.
Egg donors who have undergone multiple retrieval cycles could be good candidates for IVM. It is also a good option for those deemed "hyper-responders," patients whose "ovaries naturally develop more follicles each month, thanks to their young age or conditions such as polycystic ovary syndrome," The Atlantic said. These patients are at the highest risk for dangerous IVF side effects, like ovarian hyperstimulation syndrome, so "IVM could be a safer choice and an effective one."
It could also be helpful to cancer patients, "many of whom don't have time to undergo a lengthy IVF cycle before beginning cancer treatment that threatens their fertility," said The Atlantic. In the future, IVM could go far in reducing the "physical and emotional toll that fertility treatment takes on women at a time when more people than ever are seeking it out." Within the fertility industry, there is a "growing recognition that fertility treatments must be not only effective but also more humane," Dina Radenkovic, the CEO of biotechnology company Gameto, said to The Atlantic.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Theara Coleman has worked as a staff writer at The Week since September 2022. She frequently writes about technology, education, literature and general news. She was previously a contributing writer and assistant editor at Honeysuckle Magazine, where she covered racial politics and cannabis industry news.
-
How Trump is making your Shein and Temu orders more expensive
In the Spotlight The president has ended a tariff loophole for small shipments
By Joel Mathis, The Week US Published
-
The Aga Khan, billionaire spiritual leader, dies at 88
Speed Read Prince Karim Al-Hussaini's philanthropy funded hospitals, housing and schools in some of the world's poorest places
By Peter Weber, The Week US Published
-
At least 11 killed in Sweden adult ed school shooting
Speed Read The worst mass shooting in Swedish history took place in Orebro
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published
-
The decline of the contraceptive pill
In the Spotlight Fears of the pill's side effects, stoked by social media, behind switch to fertility trackers – or no contraception at all
By Harriet Marsden, The Week UK Published
-
What are the long-term effects of alcohol?
It's not just cancer
By Joel Mathis, The Week US Published
-
HMPV is spreading in China but there's no need to worry
The Explainer Respiratory illness is common in winter
By Devika Rao, The Week US Published
-
Walking pneumonia cases are picking up pace
The explainer Another respiratory illness to be wary of
By Devika Rao, The Week US Published
-
Marty Makary: the medical contrarian who will lead the FDA
In the Spotlight What Johns Hopkins surgeon and commentator Marty Makary will bring to the FDA
By David Faris Published
-
The future of fluoridated water is up for debate
The Explainer The oral benefits are watery
By Devika Rao, The Week US Published
-
Will the murder of a health insurance CEO cause an industry reckoning?
Today's Big Question UnitedHealthcare CEO Brian Thompson was shot and killed in what police believe was a targeted attack
By Justin Klawans, The Week US Published